Biogen Inc. (BIIB) Stock Analysis 2026

HealthcareDrug Manufacturers - General
$249.65
as of 2026-10-29
+51.5% (52-week)50D MA $207.81  |  200D MA $189.92

BriMind AI Score

Proprietary
29
Weak
Price CAGR
-1.5%
1Y Return
+67.2%
Analyst Upside
-5.8%
Rev Growth
3.4%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

BIIB Revenue & Profitability Breakdown

This chart shows how BIIB's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$10.03B
Cost of Revenue
-$2.17B
Gross Profit
$7.85B78.3% margin
Operating Expenses
-$5.34B
Operating Income
$2.51B25.1% margin
Tax & Other
-$1.68B
Net Income
$834.6M8.3% margin
Gross Margin
78.3%
Operating Margin
25.1%
Net Margin
8.3%
EBITDA Margin
31.4%

Key Financial Metrics

Biogen Inc. trades at a trailing P/E of 38.74x, generates $1.27B in free cash flow, runs a debt/equity ratio of 44.33, and converts shareholder equity into profit at a 4.6% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$32.28B
Enterprise Value
$23.53B
P/E (Trailing)
38.74
P/E (Forward)
13.21
PEG Ratio
1.54
EV / EBITDA
7.64
Price / Sales
1.99
Price / Book
1.15
Revenue
$10.03B
Revenue Growth
3.4%
Earnings Growth
-84.8%
EBITDA
$3.08B
Gross Margin
78.3%
Operating Margin
25.1%
Net Margin
8.3%
Return on Equity
4.6%
Return on Assets
5.2%
Free Cash Flow
$1.27B
Total Cash
$2.60B
Total Debt
$6.62B
Debt / Equity
44.33
Current Ratio
1.86
Quick Ratio
0.94
Beta
0.16
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
0.2%
Inst. Ownership
99.6%
Short % Float
3.9%
Book Value / Share
$127.61

Wall Street Analyst Consensus

31 analysts covering Biogen Inc. currently lean toward a Buy rating, with a mean 12-month price target of $236.22 (-5.4% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Consensus RatingBuy(31 analysts)
SellStrong Buy
Low Target$115.00-53.9%
Mean Target$236.22-5.4% upside
High Target$260.00+4.1%

Intrinsic Value Estimates for BIIB

We use 1 valuation model to estimate BIIB's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

Technical Price Signals

BIIB is currently in a golden cross pattern, trading above its 50-day average of $207.81 and above its 200-day average of $189.92. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$249.65
50-Day MA
$207.81
▲ Price above
200-Day MA
$189.92
▲ Price above
Golden Cross Pattern
Price above both MAs — bullish signal
Read the full BIIB in-depth report
Seven-method valuation, AI Score, blended price target, and a 5-year Monte Carlo simulation for BIIB.

Compare BIIB with Peers

BIIB vs REGNBiogen vs Regeneron — Alzheimer's Drug vs Dupixent Bloc
BIIB vs GILDBiogen vs Gilead — Neurology vs Antiviral & Oncology Bi
AMGN vs BIIBAmgen vs Biogen — Which Established Biotech Wins?
VRTX vs BIIBVertex vs Biogen — Which Specialty Biotech Stock Wins?
BIIB vs ALNYBiogen vs Alnylam — CNS Specialist vs RNA Interference
RARE vs BIIBUltragenyx vs Biogen — Rare Disease Growth vs CNS Turna

Further Reading

Research and guides that put BIIB’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

Market TheoryThe Stock-Split Pop Is a Myth: What 39 Real Splits Actually DidMarket Theory10-Year Treasury Yield Hits 19-Year High: What 5.2% Means for StocksRisk ManagementBest ETFs for a Recession-Proof Portfolio in 2026FundamentalsHow to Read a 10-K Annual Report: Complete Investor Guide

More Healthcare Stock Analysis

In-depth reports on companies operating alongside BIIB — business models, bull and bear cases, and the metrics that matter.

PFEPfizer Inc.Drug Manufacturers - GeneralGILDGilead Sciences, Inc.Drug Manufacturers - GeneralAMGNAmgen Inc.Drug Manufacturers - GeneralABBVAbbVie Inc.Drug Manufacturers - GeneralLLYEli Lilly and CompanyDrug Manufacturers - GeneralJNJJohnson & JohnsonDrug Manufacturers - GeneralMCKMcKesson CorporationMedical DistributionEWEdwards Lifesciences CorporationMedical Devices

Unlock the Full BIIB Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis